This finding may have immediate utility since an inhibitor of PTP1B (MSI-1436) has passed early clinical trials for treatments of type-2 diabetes, obesity, and cancer [47], and perhaps this drug can be used to attenuate HSV-1 reactivation disease in immunocompromised patients. The gene discussed is PTPN1; the disease is obesity due to melanocortin 4 receptor deficiency.